We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.

Join the Conversation

Journal of Dietary Supplements

Deadline: March 15, 2020 

Special Issue:

Cannabidiol and other cannabinoids: From toxicology and pharmacology to the development of a regulatory pathway

Cannabidiol (CBD) is a non-psychotropic ingredient of Cannabis sativa that has grown in popularity during the last decade. CBD is a major component of EPIDIOLEX®, a U. S. Food and Drug Administration (FDA)-approved drug designed for the treatment of drug-resistant pediatric epileptic seizures associated with several rare syndromes. Furthermore, CBD has been proposed as a treatment for a number of other diseases for which clinical trials are now ongoing.

Accumulating evidence indicates that the number of “CBD-containing” products, available mostly online, is growing exponentially. However, the U.S. FDA prohibits sales of CBD as a dietary supplement or ingredient in conventional food. Further, a clear regulatory quality oversight exists which leads to an uncontrolled CBD market that, in turn, threatens to result in a burst of negative health effects experienced by a trusting public.

Thus, there are a number of open questions demanding answers in the very near future: For which purposes is CBD effective? Is it safe? Is it safe for everyone? What is a future path for CBD as well as for other cannabinoids? Should CBD be allowed as a drug only, or is there a way for it to be listed as a dietary supplement and food ingredient?

This Special Issue, the first of its kind on CBD, will be devoted to answering those and other questions by publishing articles in the fields of pharmacology, toxicology, and regulation of CBD and other cannabinoids. Research manuscripts, including work performed in experimental models and clinical trials, as well as reviews and prospective papers are invited.

 

You will benefit from publishing in the Journal of Dietary Supplements by:

  1. Gain recognition from an international audience and increase your opportunities for future collaboration 
  2. Receive guidance from the prestigious and experienced members of our international Editorial Board throughout the submissions process 
  3. Receive 50 free e-prints & promotional tips on promoting your article courtesy of our Author Services site  
  4. Immediately see the impact of your research made in the community by tracking downloads, citations, and the Altmetric Score of your article on My Authored Works  
  5. Increase the discoverability of your research with PubMed/MEDLINE, EMBASE listings and more

Journal of Dietary Supplements

Visit Journal Articles

Editorial Information

Editor-in-Chief:

Taylor C. Wallace – George Mason University

Special Issue Editors:

Dr. Igor Koturbash – University of Arkansas for Medical Sciences

Dr. Douglas MacKay – CV Sciences

Submission Guidelines

Guidelines for submission to the Journal of Dietary Supplements can be viewed at the Instructions for Authors Page.

All papers will be peer-reviewed through a double-blind peer-review process.

Original, unpublished manuscripts should be submitted online at Manuscript Central  by March 15, 2020

When submitting your manuscript, please be sure to indicate that it is to be considered for the special issue on cannabidiol in your cover letter.

For further inquiries, please contact Dr. Igor Koturbash and Dr. Douglas MacKay.

Deadline for manuscript submission: March 15, 2020

Publication of the Special Issue: May 2020

Latest Tweets